Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gbt · pe ratio · data through Dec 31, 2021
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Global Blood Therapeutics, Inc. (GBT) measures how much investors pay for each dollar of the company's trailing earnings. GBT's current PE ratio of N/A is calculated by dividing its stock price of $68.49 by its TTM earnings per share of -$4.82.
Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31
PE Ratio History
2013 – 2021 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Global Blood Therapeutics, Inc.You GBT | — | N/A | — | -$4.82 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 CymaBay Therapeutics, Inc. CBAY | $3.7B | N/A | — | -$0.99 |
 IVERIC bio, Inc. ISEE | $5.5B | N/A | — | -$1.45 |
 MorphoSys AG MOR | $2.9B | N/A | — | -$1.38 |
 Morphic Holding, Inc. MORF | $2.9B | N/A | — | -$3.59 |
 Mirati Therapeutics, Inc. MRTX | $4.1B | N/A | — | -$13.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2021-12-31Latest FY2021 | — | $-4.82 | — | |
2020-12-31 FY2020 | — | $-4.04 | — | |
2019-12-31 FY2019 | — | $-4.57 | — | |
2018-12-31 FY2018 | — | $-3.41 | — | |
2017-12-31 FY2017 | — | $-2.76 | — | |
2016-12-31 FY2016 | — | $-2.48 | — | |
2015-12-31 FY2015 | — | $-3.62 | — | |
2014-12-31 FY2014 | — | $-1.51 | — | |
2013-12-31 FY2013 | — | $-0.83 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Global Blood Therapeutics, Inc. (GBT) measures how much investors pay for each dollar of the company's trailing earnings. GBT's current PE ratio of N/A is calculated by dividing its stock price of $68.49 by its TTM earnings per share of -$4.82.
Frequently asked questions
GBT pe ratio · 6 questionsGBT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $68.49 and TTM EPS of -$4.82. Data sourced from Financial Modeling Prep via GBT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Global Blood Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09